Sugi Predict

Sugi Predict / Compounds / SCHEMBL11600

SCHEMBL11600

SCHEMBL11600

[Pd].c1ccc(Pc2ccccc2)cc1.c1ccc(Pc2ccccc2)cc1.c1ccc(Pc2ccccc2)cc1.c1ccc(Pc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.38
▸ TSHR P16473 5/20 0.33
▸ ALOX12 P18054 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ MMP3 P08254 1/20 0.33
▸ BCL2L1 Q07817 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696303 1.00 TDP1 (0.41) TDP1CA1CA2CA9CA12
SCHEMBL3158336 1.00 TDP1 (0.41) TDP1CA1CA2CA9CA12
SCHEMBL28159040 0.96 TDP1 (0.39) TDP1CA1CA2CA9CA12
Benzene SCHEMBL28239903 0.96 TDP1 (0.44) TDP1CA1CA2CA9CA12
Benzene SCHEMBL28943358 0.96 TDP1 (0.44) TDP1CA1CA2CA9CA12
SCHEMBL28047489 0.96 TDP1 (0.44) TDP1CA1CA2CA9CA12
SCHEMBL49343 0.96 TDP1 (0.44) TDP1CA1CA2CA9CA12
Benzene SCHEMBL4445625 0.96 TDP1 (0.44) TDP1CA1CA2CA9CA12
Hydrochloric Acid SCHEMBL28731681 0.93 CA1 (0.37) TDP1CA1CA2CA9CA12
Ethane SCHEMBL4318566 0.93 TSHR (0.37) TDP1CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225122-A1 ZWITTERIONIC CELL-PERMEANT AND WATER-SOLUBLE RHODAMINE DYES FOR QUANTITATIVE IMAGING APPLICATIONS Oregon Health & Science University (US) 2023-08-16 — — EP disclosed
US-20220109110-A1 ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2022-04-07 — — US disclosed
US-20210380546-A1 VACCINE ADJUVANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-09 — — US disclosed
US-11161899-B2 Method using split inteins to generate protein conjugates THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2021-11-02 — — US disclosed
WO-2021085370-A1 AZOLE DERIVATIVE AND USE THEREOF クミアイ化学工業株式会社 2021-05-06 — — WO disclosed
WO-2021054161-A1 FUSED POLYCYCLIC AROMATIC COMPOUND 日本化薬株式会社 2021-03-25 — — WO disclosed
WO-2020166680-A1 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE 大鵬薬品工業株式会社 2020-08-20 — — WO disclosed
WO-2020085493-A1 NOVEL INDAZOLE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2020-04-30 — — WO disclosed
US-20200087388-A1 SPLIT INTEINS, CONJUGATES AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2020-03-19 — — US disclosed
EP-2573559-B1 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC (US) 2019-03-13 — — EP disclosed
EP-0799200-A1 SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-10-08 — — EP disclosed
WO-1996019995-A1 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1996-07-04 — — WO disclosed
WO-1996019451-A1 SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1996-06-27 — — WO disclosed
US-5340810-A Useful in the treatment and prophylaxis of depression and other disorders of the central nervous system GLAXO GROUP LIMITED (GB) 1994-08-23 — — US disclosed
US-5317019-A Antiinflammatory agents SMITHKLINE BEECHAM CORP. (US) 1994-05-31 — — US disclosed
EP-0586663-A1 CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF ZENECA LIMITED (GB) 1994-03-16 — — EP disclosed
WO-1993019070-A1 CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF ZENECA LIMITED (GB) 1993-09-30 — — WO disclosed
EP-0533268-A1 Benzanilide derivatives as 5-HT1D antagonists GLAXO GROUP LIMITED (GB) 1993-03-24 — — EP disclosed
EP-0282492-A1 ANTIMICROBIAL N-ACYL-2-AZETIDINONES THE UPJOHN COMPANY (US) 1988-09-21 — — EP disclosed
WO-1987004429-A1 ANTIMICROBIAL N-ACYL-2-AZETIDINONES THE UPJOHN COMPANY (US) 1987-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380546-A1 VACCINE ADJUVANT IFNG, TLR9, LY96 TDP1 3737/4885CA1 2692/4885CA2 3421/4885
US-20220109110-A1 ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME OR10J3, LEF1, TMEM109 TDP1 262/4885CA1 3313/4885CA2 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.